Amicogen, Inc. (KOSDAQ:092040)
 3,040.00
 -40.00 (-1.30%)
  Oct 31, 2025, 3:30 PM KST
Amicogen Revenue
Amicogen had revenue of 10.15B KRW in the quarter ending June 30, 2025, a decrease of -76.22%. This brings the company's revenue in the last twelve months to 117.72B, down -25.95% year-over-year. In the year 2024, Amicogen had annual revenue of 173.60B with 8.57% growth.
Revenue (ttm) 
 117.72B
Revenue Growth 
 -25.95%
P/S Ratio 
 1.45
Revenue / Employee 
 498.82M
Employees 
 236
Market Cap 
170.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 173.60B | 13.70B | 8.57% | 
| Dec 31, 2023 | 159.90B | 15.61B | 10.82% | 
| Dec 31, 2022 | 144.30B | 19.41B | 15.55% | 
| Dec 31, 2021 | 124.88B | 9.02B | 7.79% | 
| Dec 31, 2020 | 115.86B | 675.18M | 0.59% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| Hanmi Pharm. | 1.47T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |